Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53,087 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RNA aggregates harness the danger response for potent cancer immunotherapy.
Mendez-Gomez HR, DeVries A, Castillo P, von Roemeling C, Qdaisat S, Stover BD, Xie C, Weidert F, Zhao C, Moor R, Liu R, Soni D, Ogando-Rivas E, Chardon-Robles J, McGuiness J, Zhang D, Chung MC, Marconi C, Michel S, Barpujari A, Jobin GW, Thomas N, Ma X, Campaneria Y, Grippin A, Karachi A, Li D, Sahay B, Elliott L, Foster TP, Coleman KE, Milner RJ, Sawyer WG, Ligon JA, Simon E, Cleaver B, Wynne K, Hodik M, Molinaro AM, Guan J, Kellish P, Doty A, Lee JH, Massini T, Kresak JL, Huang J, Hwang EI, Kline C, Carrera-Justiz S, Rahman M, Gatica S, Mueller S, Prados M, Ghiaseddin AP, Silver NL, Mitchell DA, Sayour EJ. Mendez-Gomez HR, et al. Among authors: li d. Cell. 2024 May 9;187(10):2521-2535.e21. doi: 10.1016/j.cell.2024.04.003. Epub 2024 May 1. Cell. 2024. PMID: 38697107
mRNA challenge predicts brain cancer immunogenicity and response to checkpoint inhibitors.
Castillo P, Ogando-Rivas E, Geffrard H, Pepe A, Liu R, Nguyen DT, Pedro DI, Zhang D, DeVries A, Qdaisat S, Karachi A, Rahman M, Weidert F, Milner R, Huang J, Silver NL, Ligon J, Li D, Lee JH, Carrera-Justiz S, Mitchell DA, Mendez-Gomez H, Sawyer WG, Sayour EJ. Castillo P, et al. Among authors: li d. bioRxiv [Preprint]. 2023 Mar 23:2023.03.18.532056. doi: 10.1101/2023.03.18.532056. bioRxiv. 2023. PMID: 36993158 Free PMC article. Preprint.
mRNA aggregates harness danger response for potent cancer immunotherapy.
Mendez-Gomez HR, DeVries A, Castillo P, Stover BD, Qdaisat S, Von Roemeling C, Ogando-Rivas E, Weidert F, McGuiness J, Zhang D, Chung MC, Li D, Zhang C, Marconi C, Campaneria Y, Chardon-Robles J, Grippin A, Karachi A, Thomas N, Huang J, Milner R, Sahay B, Sawyer WG, Ligon JA, Silver N, Simon E, Cleaver B, Wynne K, Hodik M, Molinaro A, Guan J, Kellish P, Doty A, Lee JH, Carrera-Justiz S, Rahman M, Gatica S, Mueller S, Prados M, Ghiaseddin A, Mitchell DA, Sayour EJ. Mendez-Gomez HR, et al. Among authors: li d. medRxiv [Preprint]. 2023 Mar 17:2023.03.12.23287108. doi: 10.1101/2023.03.12.23287108. medRxiv. 2023. Update in: Cell. 2024 May 9;187(10):2521-2535.e21. doi: 10.1016/j.cell.2024.04.003 PMID: 36993772 Free PMC article. Updated. Preprint.
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
George TJ, Lee JH, DeRemer DL, Hosein PJ, Staal S, Markham MJ, Jones D, Daily KC, Chatzkel JA, Ramnaraign BH, Close JL, Ezenwajiaku N, Murphy MC, Allegra CJ, Rogers S, Zhang Z, Li D, Srinivasan G, Shaheen M, Hromas R. George TJ, et al. Among authors: li d. JCO Precis Oncol. 2024 Dec;8:e2400406. doi: 10.1200/PO-24-00406. Epub 2024 Dec 3. JCO Precis Oncol. 2024. PMID: 39626160 Free PMC article. Clinical Trial.
53,087 results
You have reached the last available page of results. Please see the User Guide for more information.